Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Indian J Med Paediatr Oncol ; 36(4): 243-8, 2015.
Article in English | MEDLINE | ID: mdl-26811594

ABSTRACT

BACKGROUND: Nephrotoxicity is one of the known side effects of methotrexate (MTX) therapy despite the use of conventional protective measures. Our objectives were to evaluate the effects of N-acetylcysteine (NAC) on MTX-induced toxicity in renal tubular cells and to evaluate whether adjunctive use of NAC interferes with MTX antitumor activity in the B-cell lymphoma. METHODS: Kidney Epithelial (Madin-Darby canine kidney [MDCK]) cells were exposed to MTX (10 µM or 100 µM) alone and with NAC (0.2 mM or 0.4 mM). Reactive oxygen species (ROS) generation at 1, 2, 4, and 24 h was measured by flow cytometer. Quantification of total glutathione (GSH) was performed by using GSH assay kit. To measure the impact of NAC on the antitumor activity of MTX, B lymphoma cells were exposed to MTX alone and with NAC. A percentage of apoptosis was measured using fluorescein isothiocyanate in both cell lines. Quantitative data was presented as a means ± standard deviation, and P values were analyzed using the Student's t-test. RESULTS: Apoptosis in MDCK cells were observed after 24 h of incubation with both 10 µM and 100 µM MTX. Maximum ROS generation was observed at 4 h and corresponded to GSH production. Treatment with 0.2 and 0.4 mM of NAC led to decrease percentages of apoptotic MDCK cells. NAC did not change either proliferation or apoptosis of B-cell lymphoma. CONCLUSION: Using NAC for kidney protection may not interfere with the antitumor activity of MTX. Further in vivo studies are warranted to confirm noninterference between MTX and NAC and assess synergistic antitumor effects.

2.
J Popul Ther Clin Pharmacol ; 20(2): e132-45, 2013.
Article in English | MEDLINE | ID: mdl-23775286

ABSTRACT

Nephrotoxicity is a serious side effect associated with ifosfamide use. It can affect up to 30% of children who are treated with this chemotherapeutic drug, and treatment may necessitate lifelong supplementations, renal dialysis, renal transplant, and in severe cases may result in death. The antioxidant n-acetylcysteine is a promising strategy for mitigating this renal toxicity. It is currently used in children for acetaminophen overdose in the 21-hour IV protocol, a dose which has also been suggested to provide renal protection against ifosfamide. Of significance, both in vitro and in vivo studies suggest n-acetylcysteine does not interfere with the antitumor actions of ifosfamide. Most importantly, n-acetylcysteine has successfully protected against ifosfamide-induced nephrotoxicity in both cell and rodent models, as well as in several paediatric cases, suggesting it should be evaluated as a treatment option for children on ifosfamide who present with renal dysfunction. The purpose of this paper is to outline strategies and recommendations for treating patients at risk or suffering from nephrotoxicity during ifosfamide therapy. These recommendations may be used when deciding who to treat, how and when to treat, as well as several considerations when exact recommendations cannot be met. They have been created to increase both the quality of care and quality of life of paediatric oncology patients.


Subject(s)
Acetylcysteine/therapeutic use , Antidotes/therapeutic use , Ifosfamide/adverse effects , Kidney Diseases/drug therapy , Acetylcysteine/administration & dosage , Animals , Antidotes/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/therapeutic use , Antioxidants/administration & dosage , Antioxidants/therapeutic use , Child , Drug Administration Schedule , Humans , Ifosfamide/therapeutic use , Kidney Diseases/chemically induced , Kidney Diseases/epidemiology , Neoplasms/drug therapy , Quality of Life
3.
J Clin Pharmacol ; 52(1): 55-64, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21263015

ABSTRACT

Ifosfamide (IFO), which is used in the treatment of pediatric solid tumors, causes high rates of nephrotoxicity. N-acetylcysteine (NAC), an antidote for acetaminophen overdose, has been shown to prevent IFO-induced renal cell death and nephrotoxicity in both LLCPK-1 cells and a rat model. To facilitate the use of NAC in preventing IFO-induced nephrotoxicity in children, the authors compared the systemic exposure to NAC in children treated for acetaminophen overdose to the systemic exposure of the therapeutically effective rat model. The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h). They also report 2 pediatric cases in which NAC-attenuated acute renal failure associated with IFO when given concurrently with their chemotherapy treatment. Systemic exposure to NAC measured in 1 of these cases was comparable to that in the children treated for acetaminophen overdose. These results corroborate NAC's potential to protect against IFO-induced nephrotoxicity in children when used in its clinically approved dose schedule and supports a clinical trial in children.


Subject(s)
Acetylcysteine/pharmacokinetics , Acetylcysteine/therapeutic use , Acute Kidney Injury/prevention & control , Protective Agents/pharmacokinetics , Protective Agents/therapeutic use , Acetaminophen/toxicity , Acetylcysteine/blood , Acute Kidney Injury/chemically induced , Acute Kidney Injury/metabolism , Adolescent , Analgesics, Non-Narcotic/toxicity , Animals , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/pharmacokinetics , Area Under Curve , Child , Drug Overdose/drug therapy , Female , Humans , Ifosfamide/adverse effects , Ifosfamide/blood , Ifosfamide/pharmacokinetics , Male , Rats , Rats, Wistar
5.
Pediatr Blood Cancer ; 51(1): 130-3, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18338395

ABSTRACT

Juvenile xanthogranuloma (JXG) is generally a benign, self-limited histiocytic disorder of the skin. We report two cases of multisystem JXG presenting with clinical features more commonly seen in Langerhans cell histiocytosis (LCH), including diabetes insipidus and lytic bony lesions. Histologically, the skin lesions demonstrated a histiocytic dermal infiltrate that stained for CD-68, but S-100 and CD1a stains were negative. Treatment according to LCH-based chemotherapy regimens resulted in prompt resolution of symptoms. A literature review of multisystem JXG cases treated with chemotherapy suggests that symptomatic patients can successfully be treated with LCH-based regimens that include both corticosteroids and vinca alkaloids.


Subject(s)
Xanthogranuloma, Juvenile/drug therapy , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Diagnosis, Differential , Female , Histiocytosis, Langerhans-Cell/diagnosis , Humans , Infant , Male , Treatment Outcome , Xanthogranuloma, Juvenile/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...